WMA
ABUS icon

Wealth Management Associates’s Arbutus Biopharma ABUS Stock Holding History

Wealth Management Associates’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$710K Buy
147,995
+16,125
+12% +$70.8K 0.2% 92
2026
Q1 		$593K Buy
131,870
+4,000
+3% +$17.5K 0.2% 100
2025
Q4 		$615K Buy
127,870
+15,050
+13% +$67.7K 0.21% 89
2025
Q3 		$512K Buy
112,820
+7,900
+8% +$29K 0.18% 102
2025
Q2 		$324K Buy
104,920
+8,500
+9% +$28.2K 0.13% 147
2025
Q1 		$337K Buy
96,420
+35,400
+58% +$118K 0.14% 133
2024
Q4 		$200K Buy
61,020
+6,500
+12% +$23.9K 0.09% 199
2024
Q3 		$210K Buy
54,520
+4,700
+9% +$18K 0.09% 195
2024
Q2 		$154K Hold
49,820
– – 0.07% 196
2024
Q1 		$154K Buy
49,820
+1,800
+4% +$4.66K 0.07% 196
2023
Q4 		$120K Sell
48,020
-6,600
-12% -$12.9K 0.06% 195
2023
Q3 		$111K Buy
54,620
+5,000
+10% +$10.5K 0.06% 186
2023
Q2 		$114K Hold
49,620
– – 0.06% 185
2023
Q1 		$150K Buy
49,620
+350
+0.7% +$987 0.09% 185
2022
Q4 		$115K Buy
49,270
+8,400
+21% +$20.1K 0.08% 181
2022
Q3 		$78.1K Buy
40,870
+11,200
+38% +$26.4K 0.06% 172
2022
Q2 		$80.4K Buy
29,670
+7,500
+34% +$19.2K 0.05% 173
2022
Q1 		$66.1K Buy
22,170
+3,600
+19% +$11K 0.04% 186
2021
Q4 		$72.2K Buy
18,570
+1,800
+11% +$6.99K 0.04% 195
2021
Q3 		$71.9K Sell
16,770
-700
-4% -$2.33K 0.04% 192
2021
Q2 		$52.9K Sell
17,470
-11,700
-40% -$36.2K 0.03% 197
2021
Q1 		$97.1K Sell
29,170
-2,400
-8% -$9.26K 0.06% 186
2020
Q4 		$112K Buy
+31,570
New +$111K 0.07% 177

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wealth Management Associates's ABUS Position: Q2 2026 in Review

Wealth Management Associates increased its Arbutus Biopharma (ABUS) stake by 12% in Q2 2026, buying an estimated $70.8K and bringing the position to 147,995 shares worth $710K. The position accounts for 0.2% of the portfolio, ranked #92.

Wealth Management Associates first reported a position in ABUS in Q4 2020 and has held it in 23 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Wealth Management Associates held 147,995 shares of Arbutus Biopharma worth $710K as of Q2 2026.
  • Wealth Management Associates bought 16,125 Arbutus Biopharma shares in Q2 2026, an estimated $70.8K.
  • Arbutus Biopharma made up 0.2% of Wealth Management Associates's portfolio in Q2 2026, its #92 holding.
  • Wealth Management Associates first reported a position in Arbutus Biopharma in Q4 2020 and has held it in 23 quarters since.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Wealth Management Associates's 13F filing for Q2 2026, filed 21 Jul 2026.